<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574311</url>
  </required_header>
  <id_info>
    <org_study_id>PREFER-CPB01</org_study_id>
    <nct_id>NCT03574311</nct_id>
  </id_info>
  <brief_title>Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery</brief_title>
  <acronym>PREFER-CABG</acronym>
  <official_title>A Phase IV Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Elective or Urgent Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vifor Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of single dose preoperative ferric
      carboxymaltose in the prevention of postoperative infections and blood transfusions in
      patients scheduled for cardiac surgery. Half of the patients will receive ferric
      carboxymaltose and half of the patients physiological saline solution as placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled 1:1</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinding, study drug administration by separate staff blinded from participant and investigators</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of allogeneic blood transfusion and/or nosocomial infection</measure>
    <time_frame>0-90 days</time_frame>
    <description>Composite of transfused red blood cell units and/or nosocomial infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>0-90 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU/CCU days</measure>
    <time_frame>0-90 days</time_frame>
    <description>Days in the ICU (intensive care unit) and/or CCU (cardiac care unit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative myocardial infarction</measure>
    <time_frame>3 days</time_frame>
    <description>MI (myocardial infarction) assessed by postoperative CK-Mbm or Troponin t levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>0-90 days</time_frame>
    <description>Days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on vasoactive drugs</measure>
    <time_frame>0-90 days</time_frame>
    <description>Days on vasopressors (e.g. epinephrine, norepinephrine, milrinone etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>0-90 days</time_frame>
    <description>Days not on ventilator (intubated or non-invasive ventilation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AKI (acute kidney injury)</measure>
    <time_frame>0-90 days</time_frame>
    <description>Rate of acute renal failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset atrial fibrillation (AF) or flutter</measure>
    <time_frame>0-90 days</time_frame>
    <description>New AF or flutter (i.e. patient without previous history of AF/flutter) assessed from ECG-telemetry during index hospitalization or ECG-verified AF/flutter after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute heart failure</measure>
    <time_frame>90 days</time_frame>
    <description>Acute congestive heart failure (diagnosed by a clinician) requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening heart failure</measure>
    <time_frame>0-90 days</time_frame>
    <description>Worsening to NYHA -class (New York Heart Association) III/IV or readmission for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed with self-reporting questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Postoperative Complications</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Mitral Valve Disease</condition>
  <condition>Aortic Aneurysm, Thoracic</condition>
  <arm_group>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative 1000 mg intravenous single dose as 30 minute infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preoperative 100 ml saline as 30 minute infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>A single dose of drug or placebo is administered preoperatively to participants</description>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiological saline</intervention_name>
    <description>Single infusion 100 ml physiological saline infusion preoperatively</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients presenting with cardiac disease requiring surgical operation

          2. Open heart surgery is consideredas the best appropriate treatment strategy according
             to the current guidelines.

               -  significant three vessel disease

               -  left main disease Â± single, two or three vessel disease

               -  two-vessel disease with proximal LAD stenosis

               -  coronary artery disease requiring revascularization not amenable to percutaneous
                  coronary intervention

               -  Aortic valve disease requiring aortic valve surgery

               -  Mitral valve disease requiring surgical mitral surgery

               -  Combined surgery for revascularization and valve disease

               -  surgery of ascending aorta

          3. Have provided signed written informed consent

        Exclusion Criteria:

          1. Age &lt; 35 years

          2. Patients requiring , emergency or salvage cardiac surgical operation

          3. Participation in another clinical study or treatment with another investigational
             product 30 days prior to randomization

          4. Moribund patient not expected to survive surgery 12 months after surgery

          5. Active malignant disease with a short life expectancy, not eligible for surgery

          6. Hemoglobin levels &gt; 155 g/dL for women and &gt;167 g/dl for men (upper reference limits
             for TYKSlab)

          7. Ferritin levels &gt;150 ug/l for women and &gt;400 ug/l for men.

          8. Renal dialysis therapy for chronic renal failure or severe preoperative renal
             impairment (eGFR&lt;30ml/min).

          9. Study treatment can't be infused during the required time window: minimum 48 hours and
             maximum 21 days before the operation.

         10. Ongoing oral or parenteral iron medication at the time of randomization

         11. Iron or haemoglobin metabolism or synthesis disorders

         12. Primary or secondary hemochromatosis (in males and postmenopausal females, a serum
             ferritin value of over 300 ng/mL (670 pmol/L); and in premenopausal females, a serum
             ferritin value of over 150[17] or 200[18] ng/mL (330 or 440 pmol/L) indicates iron
             overload).

         13. Porphyria cutanea tarda.

         14. Liver failure (Child-Pugh class B or C).

         15. Pregnancy.

         16. Body weight less than 50kg.

         17. Ongoing antibiotic treatment other than prophylactic urine tract infection
             antibiotics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jarmo M Gunn, adj. professor</last_name>
    <phone>+35823130000</phone>
    <email>jarmo.gunn@tyks.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tuija Vasankari, RN</last_name>
    <phone>+35823130000</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarmo M Gunn, PhD</last_name>
      <phone>+35823130548</phone>
      <email>jarmo.gunn@tyks.fi</email>
    </contact>
    <contact_backup>
      <last_name>Tuija Vasankari, RN</last_name>
      <phone>+35823130000</phone>
      <email>tuija.vasankari@tyks.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CABG</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>blood transfusion</keyword>
  <keyword>intravenous iron</keyword>
  <keyword>postoperative infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

